Weaker Reimbursement Rates and a Lowered Guide Reprice GeneDx

TL;DR — GeneDx lost half its value yesterday after missing first-quarter earnings and cutting full-year revenue expectations. The company grew its testing volume by 34%, but lower insurance payouts and weak non-core sales wiped out the financial benefit. Now, the market is repricing the stock as management scrambles to cut costs and hit profitability by year-end.

The move

GeneDx dropped 49.2%, falling from a previous close of $67.93 to settle at $34.51. This represents a sharp reversal for a stock that had previously posted multi-thousand-percent returns during a historic 2024 run. The market erased those accumulated gains in a single session after the fundamental earnings data failed to support the elevated valuation.

What drove it

The headlines focused on the top-line miss, but the real damage lies in the unit economics. GeneDx posted $102.3 million in first-quarter sales, missing Wall Street estimates by roughly $10 million. Its adjusted loss of $0.28 per share came in a full $0.26 wider than expected. The core exome and genome testing business actually grew volume by 34%, but that demand did not translate to the bottom line. Chief Executive Officer Katherine Stueland noted the revenue shortfall was driven by lower-than-expected reimbursement payouts alongside underperforming non-core business lines (per MarketBeat: "prompting a channel-by-channel review and a reduction to full-year guidance"). The blended average reimbursement rate — the actual dollar amount health insurers pay out per test — dropped to $3,300. That is $200 below internal expectations. Consequently, management lowered its 2026 revenue forecast from a prior midpoint of $547.5 million down to $482.5 million.

The bigger picture

This is the classic bottleneck of the genetic testing industry. A company can build incredible artificial intelligence models for next-generation sequencing, and doctors can order the tests, but the ultimate gatekeeper is the health insurance provider. When a diagnostic company expands into new markets to chase volume, they often encounter a lag in coverage. They run the tests, they deliver the clinical reporting, and then they fight to get paid. If the payor denies the claim or reimburses at a lower tier, the testing company eats the cost. GeneDx is caught in this exact trap. They are doing more work for less money. Now, management is pivoting hard toward their high-value, foundational pediatric and neonatal intensive care diagnostics while cutting $25 million in operating expenses. To survive and attract a premium multiple in genomic testing, a company must eventually prove that its test volumes can outgrow the persistent drag of reimbursement pressure. Yesterday, GeneDx proved the opposite is happening right now.

Macro overlay

The broader market offered a strong tailwind that GeneDx entirely ignored. The Nasdaq Composite rose 1.03% and the S&P 500 gained 0.80% as market volatility cooled, sending the VIX down nearly 5%. With the 10-year Treasury yield slipping to 4.42%, conditions were ripe for growth and technology stocks to catch a bid, but GeneDx's idiosyncratic earnings failure kept it disconnected from the green screens.

What to watch

• The execution of the newly announced $25 million operating expense reduction plan over the next two quarters.
• The blended average reimbursement rate in Q2 — watch to see if it stabilizes above the $3,300 mark or slips further as the product mix shifts.
• Management's progress toward their stated goal of reaching adjusted profitability by the end of 2026.
• Growth metrics in the foundational pediatric and NICU channels, which now serve as the required anchor for the company's revised full-year guidance.